title: The dose-dependent macular thickness changes assessed by fd-oct in patients with retinitis pigmentosa treated with ciliary neurotrophic factor.
abstract: OBJECTIVE
  To evaluate the effect of intravitreal ciliary neurotrophic factor (CNTF) implant on mean macular thickness (MMT) in eyes with retinitis pigmentosa using high-resolution Fourier domain optical coherence tomography imaging.
  
  
  METHODS
  A cohort of 8 patients (CNTF-3: n = 5; CNTF-4: n = 3) enrolled in Neurotech sponsored Phase 2 clinical trial underwent Fourier domain optical coherence tomography imaging. A ≥3% change in MMT from baseline or fellow eye was considered as a measurable change.
  
  
  RESULTS
  Two patients enrolled in the CNTF-3 study received low-dose implant. At 18 months, a change in MMT from -4.47 μm to 6 μm from baseline was noted. Six patients received high-dose implant (CNTF-3: n = 3; CNTF-4: n = 3). In CNTF-3 group, 1 eye showed an increase in MMT by 19.25 μm (+7.6%) from baseline at 18 months. In CNTF-4 group, 1 eye had an increase in MMT of 27.08 μm (+11%) from baseline at 30 months; second eye had increase in MMT of 31.36 μm (+12%) from contralateral eye. Amongst these 3 responsive high-dose implant eyes, overall thickening of the retina could not be attributed to any specific retinal layer.
  
  
  CONCLUSIONS
  A heterogeneous dose-dependent response on MMT was noted in eyes treated using intravitreal CNTF implant for retinitis pigmentosa. We recommend corroboration of our findings with Neurotech sponsored clinical trial results.
authors.affiliation: Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, California.
authors.forename: Suman
authors.initials: S
authors.lastname: Pilli
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Zawadzki
authors.forename: David G
authors.initials: DG
authors.lastname: Telander
mesh_terms: D000328:Adult; D000368:Aged; D020934:Ciliary Neurotrophic Factor / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004343:Drug Implants; D005260:Female; D005583:Fourier Analysis; D006801:Humans; D021621:Imaging, Three-Dimensional; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D011446:Prospective Studies; D012160:Retina / Q000473:pathology*; D012174:Retinitis Pigmentosa / Q000175:diagnosis / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D020934:Ciliary Neurotrophic Factor; D004343:Drug Implants